Blood vessel support for curing coronary heart disease

A vascular stent and coronary heart disease technology, applied in the field of vascular stents for the treatment of coronary heart disease, can solve problems such as distribution limitations, and achieve the effects of avoiding thrombosis, optimizing functions, and inhibiting the proliferation of smooth muscle cells.

Active Publication Date: 2010-08-04
JW MEDICAL SYSTEMS LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are 7 family series of FGF (Schott RJ, Morrow LA.[J].Cardiovascres, 1993; 27(7): 1155-1161), among which acidic fibroblast growth factor (aFGF) and alkaline fibroblast growth factor (aFGF) are more studied. Fibroblast growth factor (bFGF), aFGF is composed of 140 amino acids, bFGF is composed of 146 amino acids, the amino acid sequence of the two is about 53% the same, bFGF is widely distributed, found in vascular endothelium, vascular smooth muscle, cardiomyocytes And in tissues and organs rich in blood vessels, the distribution of aFGF is relatively limited, and there is no report of its distribution in the vascular endothelium

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood vessel support for curing coronary heart disease
  • Blood vessel support for curing coronary heart disease
  • Blood vessel support for curing coronary heart disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1, the preparation of vascular stent of the present invention

[0035] Taking the 2.5mm×14mm bracket as an example to introduce the manufacturing process and main parameters of the bracket:

[0036] Add 10.0g of polylactic acid (racemic polylactic acid) with a viscosity of 0.9dl / g to 4.5g of rapamycin, put it in a clean beaker, add 100ml of ethyl acetate at 0-60°C at 500 rpm Minute mixing for 10 minutes, and then ultrasonic at 20KHZ for 20 minutes, the resulting solution is the coating solution, that is, the coating solution on the side of the bare metal stent in contact with the blood vessel wall.

[0037] Add 10.0 g of polylactic acid (racemic polylactic acid) with a viscosity of 0.9 dl / g to 1.0 g of pcDNA3-VEGF165 plasmid (purchased from Beijing Yili Hi-Tech Biotechnology Research Institute Co., Ltd., pcDNA3-VEGF 165 is based on pcDNA3.1 Departure plasmid, the recombinant plasmid capable of expressing human VEGF165 obtained by inserting the coding gene fr...

Embodiment 2

[0043] Embodiment 2, preparation of vascular stent of the present invention

[0044] Taking the 2.75mm×14mm bracket as an example to introduce the manufacturing process and main parameters of the bracket:

[0045] Add 2.5g rapamycin to 10.0g polylactic acid (racemic polylactic acid) with a viscosity of 0.2dl / g, put it in a clean beaker, add 100ml of acetone at 0-60°C at 500 rpm Mixing for 10 minutes, and then ultrasonicating at 20KHZ for 20 minutes, the resulting solution is the coating solution, that is, the coating solution on the side of the bare metal stent contacting the blood vessel wall is prepared.

[0046]Add 0.03g of pcDNA3-VEGF165 plasmid (purchased from Beijing Yili Hi-Tech Biotechnology Research Institute Co., Ltd., to 10.0g of polylactic acid with a viscosity of 0.2dl / g, pcDNA3-VEGF165 is a plasmid starting from pcDNA3.1 and inserted into human VEGF165 A recombinant plasmid that can express human VEGF165 obtained from the coding gene fragment), add 100ml of acet...

Embodiment 3

[0052] Embodiment 3, the preparation of vascular stent of the present invention

[0053] Taking the 3.0mm×14mm bracket as an example to introduce the manufacturing process and main parameters of the bracket:

[0054] Add 10.0g of polylactic acid with a viscosity of 1.2dl / g to 15g of rapamycin, put it in a clean beaker, add 100ml of chloroform, mix at 500 rpm for 10 minutes at 0-60°C, and then sonicate at 20KHZ After 20 minutes, the obtained solution is the coating solution, that is, the coating solution on the side where the bare metal stent contacts the blood vessel wall.

[0055] Add 10.0 g polylactic acid with a viscosity of 1.0 to 10.0 g pcDNA3-VEGF165 plasmid (purchased from Beijing Yili Hi-Tech Biotechnology Research Institute Co., Ltd., pcDNA3-VEGF165 is obtained by inserting the coding gene fragment of human VEGF165 from pcDNA3.1 A recombinant plasmid that can express human VEGF165), add 100ml of chloroform and mix at 500 rpm at 0-60°C for 10 minutes, then ultrasonica...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses a vascular stent that can treat the coronary heart disease. The stent comprises a bare metal stent, a coating that contacts one side of a vascular wall of the bare metal stent and a coating that contacts a side of a vascular cavity of the bare metal stent; the coating that contacts the side of the vascular wall of the bare metal stent is a mixture of a recombinant expression vector that can express human vascular endothelial growth factors or human fibroblasts and degradable polymers; the coating that contacts the side of the vascular cavity of the bare metal stent is a mixture of genes that promote the vascular endothelialization and degradable polymers. The vascular stent that can treat the coronary heart disease of the sent optimizes the functions of the stent more through an unsymmetrical coating manufacture techniques, meanwhile, a series of problems caused by smooth muscle cell proliferation, vascular endothelialization delay and polymer permanent residue, thus improving the treatment effect of the coronary heart disease stent in the maximal degree.

Description

technical field [0001] The invention relates to a blood vessel stent for treating coronary heart disease. Background technique [0002] There are two types of stents currently used for the treatment of coronary heart disease: bare metal stents (BMS) and drug-eluting stents (DES). Bare metal stents are mainly made of 316L stainless steel and cobalt-chromium alloy. DES is a stent that combines bare metal stents, polymers, and anti-restenosis drugs (the polymer is the carrier that carries the drugs onto the bare metal stents), and is divided into the following categories according to the anti-restenosis drugs carried by the stents: Rapamycin and its derivatives eluting stent (such as Cypher produced in the United States TM and Endeaver TM ; Firebird made in China TM 、Partner TM and EXCEL TM etc.) and paclitaxel-eluting stents (such as TAXUS produced in the United States TM series of stents) two types; according to whether the polymer used in the stent is degradable or no...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61L31/02A61L31/16A61F2/82A61L31/12A61L31/10
Inventor 张玉霄王吉成
Owner JW MEDICAL SYSTEMS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap